Company insight
egenerative joint disease, also known as osteoarthritis, occurs in a large number of people all around the globe, and new estimates suggest that one in three people between the ages 18–64 have arthritis. Osteoarthritis usually gets worse with ageing, causing stiffness and inflammation. It can lead to side effects such as sleep issues and depression, which negatively impacts quality of life. The social and economic consequences are only expected to increase as life expectancy advances globally. It is, therefore, of particular importance for all societies to promote healthier lifestyle initiatives, with balanced diets supported by supplements of high quality. The market size for joint health supplements is expected to reach $9bn by 2025, occupying a strong share of the total market for health supplements. ZPD takes great pride in being able to contribute with its share of expertise and solutions for the joint health market. The company has now been a front runner for chondroitin sulphate for two decades with its branded ingredient ScanDroitin.
Movement with ease D
With more than 20 years of expertise in manufacturing ingredients for joint health supplements, ZPD has become a trustworthy partner that is well known for its reliability and credibility. The goal of the company is to continuously strive to create more sustainable, safe and available solutions that benefit an ageing and increasingly active world population.
The key to success is through movement. ScanDroitin is a safe solution and, soon, Movagain will offer even greater possibilities for the joint health market.
In recent years, research has made great progress in understanding the various functions of the actions on the joint of the knee. However, newer studies indicate that the knee’s efficacy may be inhibited due to high content of related substances, which is why ZPD has undergone a highly specialised purity test to confirm the high purity of its ingredient. The company takes great
“Degenerative joint disease, also known as osteoarthritis, occurs in a large number of people all around the globe, and new estimates suggest that one in three people between the ages 18–64 have arthritis.”
Chondroitin sulphate has several functions. It delivers nutrients to the joint cartilage, helps to inhibit the enzymes that decompose the joint cartilage and speeds up the formation of a new joint cartilage. As a result, the elasticity and plasticity, which are the functions of the joint cartilage, can be maintained through the use of chondroitin sulphate.
52
pride in being able to fully customise its products, and to offer customer tailored solutions, ensuring only the best possible formulation and final product. High-quality products start with high- quality ingredients, sourced with the farm-to-fork strategy in mind. Today, consumers expect products that are sustainable, less wasteful and for
manufacturers to become more environmentally concerned. ZPD’s latest initiative, on the subject of sustainability, is to integrate environmental management into the current quality management system, forming one management system to cover quality, environment and health and safety. The changes are a guarantor for including environmental concerns in every aspect of its business, and ensuring an eco-friendlier production.
A new path
By 2022, ZPD will launch its newest proprietary product Movagain, which is intended for joint health supplements. Movagain is a nature-sourced formula with an exclusive combination of collagen type II and chondroitin sulphate. The new ingredient will enter its planned tests to document the product’s biological activity on an induced arthritic condition. Through scientific and analytical procedures, this study will provide documentation of the anti-arthritic abilities of Movagain and, from this, highlight its biological capabilities. ●
www.zpd.dk Ingredients Insight /
www.ingredients-insight.com
ESB Professional/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112
